Active — Not RecruitingNot Applicable

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

Austria, Belgium509 participantsStarted 2023-06-12

Plain-language summary

To describe the effectiveness, treatment patterns, quality of life, and safety of participants with moderately or severely active UC treated with filgotinib in a real-world setting.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Participation in any interventional or non-interventional study without prior approval from the medical leader. This does not preclude inclusion of participants enrolled to national registries.
✕. Participant is diagnosed with Crohn's disease.

What they're measuring

Treatment Persistence Rate at week 52.

Timeframe: Week 52

Trial details

NCT IDNCT05817942

SponsorAlfasigma S.p.A.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-12

View on ClinicalTrials.gov More Ulcerative Colitis trials